145 related articles for article (PubMed ID: 29398458)
1. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Greco F; Inferrera A; La Rocca R; Navarra M; Casciaro M; Grosso G; Gangemi S; Ficarra V; Mirone V
Eur Urol Focus; 2019 May; 5(3):497-507. PubMed ID: 29398458
[TBL] [Abstract][Full Text] [Related]
2. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
3. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
4. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
5. Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues.
Ambrozkiewicz F; Karczmarski J; Kulecka M; Paziewska A; Cybulska M; Szymanski M; Dobruch J; Antoniewicz A; Mikula M; Ostrowski J
Biomed Res Int; 2020; 2020():9086829. PubMed ID: 32462034
[TBL] [Abstract][Full Text] [Related]
6. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
7. Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.
Sancer O; Koşar PA; Tefebaşı MY; Ergün O; Demir M; Koşar A
Turk J Med Sci; 2022 Jun; 52(3):788-795. PubMed ID: 36326314
[TBL] [Abstract][Full Text] [Related]
8. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.
Dai X; Fang X; Ma Y; Xianyu J
Medicine (Baltimore); 2016 May; 95(18):e3493. PubMed ID: 27149447
[TBL] [Abstract][Full Text] [Related]
9. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
10. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
11. miRNA-21 as High Potential Prostate Cancer Biomarker in Prostate Cancer Patients in Indonesia.
Gunawan RR; Astuti I; Danarto HR
Asian Pac J Cancer Prev; 2023 Mar; 24(3):1095-1099. PubMed ID: 36974566
[TBL] [Abstract][Full Text] [Related]
12. Regulation of microRNAs by rape bee pollen on benign prostate hyperplasia in rats.
Chen X; Wu RZ; Ren ZM; Tong YL; Chen S; Yang F; Dai GH
Andrologia; 2020 Feb; 52(1):e13386. PubMed ID: 31733069
[TBL] [Abstract][Full Text] [Related]
13. The MicroRNAs (miRNAs) Expression in Benign Urological Diseases: A Systematic Review.
Atayi M; Mahdavi N; Salehi-Pourmehr H; Pashazadeh F; Kouchakali G; Mirzaei Z; Barati T; Abed S; Fattahi F; Hajebrahimi S
Urol J; 2024 May; ():. PubMed ID: 38733231
[TBL] [Abstract][Full Text] [Related]
14. Clinical Investigation of Chemotherapeutic Resistance and miRNA Expressions in Head and Neck Cancers: A Thorough PRISMA Compliant Systematic Review and Comprehensive Meta-Analysis.
Jayaraj R; Polpaya K; Kunale M; Kodiveri Muthukaliannan G; Shetty S; Baxi S; Mani RR; Paranjothy C; Purushothaman V; Kayarohanam S; Janakiraman AK; Balaraman AK
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553594
[No Abstract] [Full Text] [Related]
15. Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients.
Haj-Ahmad TA; Abdalla MA; Haj-Ahmad Y
J Cancer; 2014; 5(3):182-91. PubMed ID: 24563673
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
17. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.
Al-Kafaji G; Said HM; Alam MA; Al Naieb ZT
Oncol Lett; 2018 Jul; 16(1):1357-1365. PubMed ID: 30061955
[TBL] [Abstract][Full Text] [Related]
18. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
19. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis.
Perera M; Roberts MJ; Doi SA; Bolton D
Eur Urol; 2015 Apr; 67(4):704-13. PubMed ID: 25466940
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profiles in benign prostatic hyperplasia.
Zhang N; Li Z; Bai F; Ji N; Zheng Y; Li Y; Chen J; Mao X
Mol Med Rep; 2018 Mar; 17(3):3853-3858. PubMed ID: 29359788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
